JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, P. J.
Right arrow Articles by Kau, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, P. J.
Right arrow Articles by Kau, D. L.

Disposition of dobutamine in the dog

PJ Murphy, TL Williams and DL Kau

The disposition of dobutamine, a potent inotropic catecholamine, has been examined in the dog. A sensitive assay has been developed for dobutamine allowing the measurement of the drug at plasma concentrations as low as 1 ng/ml. The short plasma half-life of dobutamine from the plasma to the tissue. When 14C-dobutamine was administered, the plasma half-life of radioactivity was 1.9 hours. The circulating radioactivity consists mainly of the glucuronide conjugate of 3-O-methyldobutamine. During continuous intravenous administration of dobutamine, plasma levels of metabolites reached a maximum between 3 and 4 hours. During a 48-hour time period after administration of 14C- dobutamine, 67% of the radiolable was excreted in the urine and 20% in the feces. In dogs having cannulated bile ducts, 30 to 35% of the administered drug was excreted in the bile. The major urinary metabolites were the glucuronide conjugates of dobutamine and 3-O- methyldobutamine.

Volume 199, Issue 2, pp. 423-431, 11/01/1976
Copyright © 1976 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
A. Alonen, O. Aitio, K. Hakala, L. Luukkanen, M. Finel, and R. Kostiainen
BIOSYNTHESIS OF DOBUTAMINE MONOGLUCURONIDES AND GLUCURONIDATION OF DOBUTAMINE BY RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos., May 1, 2005; 33(5): 657 - 663.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Yan, L. T. Webster Jr., and J. L. Blumer
3-O-Methyldobutamine, a Major Metabolite of Dobutamine in Humans
Drug Metab. Dispos., May 1, 2002; 30(5): 519 - 524.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Yan, L. T. Webster Jr., and J. L. Blumer
Kinetic Interactions of Dopamine and Dobutamine with Human Catechol-O-methyltransferase and Monoamine Oxidase in Vitro
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 315 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. J Penny, H. Chen, and J. J Smolich
Increased aortic blood pressure contributes to potentiated dobutamine inotropic responses after systemic NO synthase inhibition in sheep
Cardiovasc Res, November 1, 1998; 40(2): 282 - 289.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
G. S. Francis and S. L. Archer
Diagnosis and Management of Acute Congestive Heart Failure in the Intensive Care Unit
J Intensive Care Med, March 1, 1989; 4(2): 84 - 92.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics.